-
摘要: 维A酸X受体(RXR)是配体依赖的核转录因子, 在调节一系列生理病理过程中起重要作用。在分子水平上, RXR与多个信号通路相互作用, 调控细胞生长、分化、生存与死亡等靶基因的表达。RXR信号通路网络与其他信号通路之间的相互作用使RXR成为抗肿瘤药物作用的新靶点。本文就RXR信号通路在白血病发生发展中的作用进行简要综述。Abstract: Retinoid X receptor (RXR) acts as ligand-dependent transcription factors playing an important role in regulating a serial of physiological processes, such as embryo development and organ homeostasis. At the molecular level, RXRs exert their functions by inter-activating with multiple signal pathways to regulate target gene expression which control cell growth, differentiation, survival and death. The interference in the network of RXR and other signal pathways has turned RXR into an attractive drug target.
-
Key words:
- Retinoid X receptor /
- Signal pathway /
- Leukemia /
- Bone marrow transplantation
-
Figure 1. Simplified diagram of the RXR/RAR signaling network
Cyclic adenosine monophosphate(cAMP)-protein kinase A (PKA) signal pathway activation induce leukemia cell apoptosis and differentiation. Janus kinase-signal transducer and activator of transcription (JAK-STAT) 3 signal pathway induce leukemia cells apoptosis. Activate MEK pathway show different effect on gene transcription mediated by RXRE
-
[1] Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the big bang[J]. Cell, 2014, 157(1):255-266. doi: 10.1016/j.cell.2014.03.012 [2] Piskunov A, Al Tanoury Z, Rochette-Egly C. Nuclear and extra-nuclear effects of retinoid acid receptors: how they are interconnected[J]. Subcell Biochem, 2014, 70:103-127. doi: 10.1007/978-94-017-9050-5 [3] le Maire A, Bourguet W. Retinoic acid receptors: structural basis for coregulator interaction and exchange[J]. Subcell Biochem, 2014, 70:37-54. doi: 10.1007/978-94-017-9050-5 [4] Rastinejad F. Retinoid X receptor and its partners in the nuclear receptor family[J]. Curr Opin Struct Biol, 2001, 11(1):33-38. doi: 10.1016/S0959-440X(00)00165-2 [5] Thomas M, Sukhai MA, Kamel-Reid S. An emerging role for retinoid X receptor α in malignant hematopoiesis[J]. Leuk Res, 2012, 36(9):1075-1081. doi: 10.1016/j.leukres.2012.05.022 [6] Altucci L, Leibowitz MD, Ogilvie KM, et al. RAR and RXR modulation in cancer and metabolic disease[J]. Nat Rev Drug Discov, 2007, 6(10):793-810. doi: 10.1038/nrd2397 [7] Tedesco J, Qualtieri J, Head D, et al. High prevalence of obesity in acute promyelocytic leukemia (APL): implications for differentiating agents in APL and metabolic syndrome[J]. Ther Adv Hematol, 2011, 2(3):141-145. doi: 10.1177/2040620711408490 [8] Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable[J]. Blood, 2008, 111(5):2505-2515. doi: 10.1182/blood-2007-07-102798 [9] Zeisig BB, Kwok C, Zelent A, et al. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation[J]. Cancer Cell, 2007, 12(1):36-51. doi: 10.1016/j.ccr.2007.06.006 [10] Dong S, Stenoien DL, Qiu J, et al. Reduced intranuclear mobility of APL fusion proteins accompanies their mislocalization and results in sequestration and decreased mobility of retinoid X receptor alpha[J]. Mol Cell Biol, 2004, 24(10):4465-4475. doi: 10.1128/MCB.24.10.4465-4475.2004 [11] Qiu JJ, Lu X, Zeisig BB, et al. Leukemic transformation by the APL fusion protein PRKAR1A-RAR{alpha} critically depends on recruitment of RXR{alpha}[J].Blood, 2010, 115(3):643-652. doi: 10.1182/blood-2009-07-232652 [12] Rush EA, Pollock SL, Abecassis I, et al. Interaction with RXR is necessary for NPM-RAR-induced myeloid differentiation blockade[J]. Leuk Res, 2013, 37(12):1704-1710. doi: 10.1016/j.leukres.2013.09.024 [13] Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors[J]. Genes Dev, 2000, 14(2):121-141. http://cn.bing.com/academic/profile?id=2156575042&encoded=0&v=paper_preview&mkt=zh-cn [14] Perissi V, Rosenfeld MG. Controlling nuclear receptors: the circular logic of cofactor cycles[J]. Nat Rev Mol Cell Biol, 2005, 6(7):542-554. doi: 10.1038/nrm1680 [15] Laursen KB, Wong PM, Gudas LJ. Epigenetic regulation by RARα maintains ligand-independent transcriptional activity[J]. Nucleic Acids Res, 2012, 40(1):102-115. doi: 10.1093/nar/gkr637 [16] Lengfelder E, Saussele S, Weisser A, et al. Treatment concepts of acute promyelocytic leukemia[J]. Crit Rev Oncol Hematol, 2005, 56(2):261-274. doi: 10.1016/j.critrevonc.2004.08.009 [17] Altucci L, Rossin A, Raffelsberger W, et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL[J]. Nat Med, 2001, 7(6):680-686. doi: 10.1038/89050 [18] Altucci L, Gronemeyer H. Retinoids and TRAIL: two cooperating actors to fight against cancer[J]. Vitam Horm, 2004, 67:319-345. doi: 10.1016/S0083-6729(04)67017-8 [19] Zhu J, Nasr R, Pérès L, et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo[J]. Cancer Cell, 2007, 12(1):23-35. doi: 10.1016/j.ccr.2007.06.004 [20] Tanaka T, De Luca LM. Therapeutic potential of "rexinoids" in cancer prevention and treatment[J]. Cancer Res, 2009, 69(12):4945-4947. doi: 10.1158/0008-5472.CAN-08-4407 [21] Rice KL, de Thé H. The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies[J]. J Intern Med, 2014, 276(1):61-70. doi: 10.1111/joim.12208 [22] Guillemin MC, Raffoux E, Vitoux D, et al. Invo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia[J]. J Exp Med, 2002, 196(10):1373-1380. doi: 10.1084/jem.20021129 [23] Zhao Q, Tao J, Zhu Q, et al. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation[J]. Leukemia, 2004, 18(2):285-292. doi: 10.1038/sj.leu.2403226 [24] Altucci L, Rossin A, Hirsch O, et al. Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor[J]. Cancer Res, 2005, 65(19):8754-8765. doi: 10.1158/0008-5472.CAN-04-3569 [25] Kamashev D, Vitoux D, De Thé H. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation[J]. J Exp Med, 2004, 199(8):1163-1174. doi: 10.1084/jem.20032226 [26] Gaillard E, Bruck N, Brelivet Y, et al. Phosphorylation by PKA potentiates retinoic acid receptor alpha activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7[J]. Proc Natl Acad Sci U S A, 2006, 103(25):9548-9553. doi: 10.1073/pnas.0509717103 [27] Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation[J]. Nat Med, 2008, 14(12):1333-1342. doi: 10.1038/nm.1891 [28] Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosin[J]. Lancet, 2005, 365(9464):1054-1061. doi: 10.1016/S0140-6736(05)74230-6 [29] Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation[J]. Blood, 2006, 108(10):3548-3555. doi: 10.1182/blood-2005-12-013748 [30] Gaikwad A, Rye CL, Devidas M, et al. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia[J]. Br J Haematol, 2009, 144(6):930-932. doi: 10.1111/bjh.2009.144.issue-6 [31] Hornakova T, Staerk J, Royer Y, et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers[J]. J Biol Chem, 2009, 284(11):6773-6781. doi: 10.1074/jbc.M807531200 [32] Hughes PJ, Zhao Y, Chandraratna RA, et al. Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways[J]. J Cell Biochem, 2006, 97(2):327-350. doi: 10.1002/(ISSN)1097-4644 [33] Mann KK, Padovani AM, Guo Q, et al. Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation[J]. J Clin Invest, 2005, 115(10):2924-2933. doi: 10.1172/JCI23628 [34] Battle TE, Roberson MS, Zhang T, et al. Retinoic acid-induced blr1 expression requires RARalpha, RXR, and MAPK activation and uses ERK2 but not JNK/SAPK to accelerate cell differentiation[J]. Eur J Cell Biol, 2001, 80(1):59-67. doi: 10.1078/0171-9335-00141 [35] Park EJ, Kiselev E, Conda-Sheridan M, et al. Induction of apoptosis by 3-amino-6-(3-aminopropyl)-5, 6-dihydro-5, 11-dioxo-11H-indeno[1, 2-c]isoquinoline via modulation of MAPKs (p38 and c-Jun N-terminal kinase) and c-Myc in HL-60 human leukemia cells[J]. J Nat Prod, 2012, 75(3):378-384. [36] Rochette-Egly C. Nuclear receptors: integration of multiple signaling pathways through phosphorylation[J]. Cell Signal, 2003, 15(4):355-366. doi: 10.1016/S0898-6568(02)00115-8 [37] Ishaq M, Fan M, Natarajan V. Accumulation of RXR alpha during activation of cycling human T lymphocytes: modulation of RXRE transactivation function by mitogen-activated protein kinase pathways[J]. J Immunol, 2000, 165(8):4217-4125. doi: 10.4049/jimmunol.165.8.4217 [38] Ishaq M, Fan M, Wigmore K, et al. Regulation of retinoid X receptor responsive element-dependent transcription in T lymphocytes by Ser/Thr phosphatases: functional divergence of protein kinase C (PKC)theta; and PKC alpha in mediating calcineurin-induced transactivation[J]. J Immunol, 2002, 169(2):732-738. doi: 10.4049/jimmunol.169.2.732